<code id='01B2BB3DC4'></code><style id='01B2BB3DC4'></style>
    • <acronym id='01B2BB3DC4'></acronym>
      <center id='01B2BB3DC4'><center id='01B2BB3DC4'><tfoot id='01B2BB3DC4'></tfoot></center><abbr id='01B2BB3DC4'><dir id='01B2BB3DC4'><tfoot id='01B2BB3DC4'></tfoot><noframes id='01B2BB3DC4'>

    • <optgroup id='01B2BB3DC4'><strike id='01B2BB3DC4'><sup id='01B2BB3DC4'></sup></strike><code id='01B2BB3DC4'></code></optgroup>
        1. <b id='01B2BB3DC4'><label id='01B2BB3DC4'><select id='01B2BB3DC4'><dt id='01B2BB3DC4'><span id='01B2BB3DC4'></span></dt></select></label></b><u id='01B2BB3DC4'></u>
          <i id='01B2BB3DC4'><strike id='01B2BB3DC4'><tt id='01B2BB3DC4'><pre id='01B2BB3DC4'></pre></tt></strike></i>

          Home / comprehensive / leisure time

          leisure time


          leisure time

          author:explore    Page View:96
          Illustration of two DNA strands made of banknotes. -- health coverage from STAT
          Adobe

          The staff of the Institute for Clinical and Economic Review, or ICER, are known as the nerds of the drug industry: bespectacled killjoys who emerge a few times a year to scold drugmakers for pricing their latest cancer or MS advance far beyond reason.

          But last year, they sat down and concluded a forthcoming treatment was worth up to $3.9 million — more than any medicine in history, more than a 45-year supply of Humira, the autoimmune drug often held up as an emblem of America’s runaway drug spending. 

          advertisement

          It was a testament to the power of a new class of gene therapies to deliver something pharma so rarely does: Genuine cures. The treatment, approved last week as Lenmeldy, may allow some babies born with an ultra-rare neurodegenerative disease called metachromatic leukodystrophy, or MLD, to grow up and live essentially normal lives.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In